The Undeniable Fact of a Pro-Big-Business Supreme Court

Three years ago, Professor Richard Epstein of the University of Chicago was peddling falsehoods and misconceptions about malpractice law that wouldn’t pass a 1L Torts class. Via Walter Olson, I see he’s back with a piece titled, “The Myth of a Pro-Business SCOTUS,” claiming “Commentators inaccurately condemn the five conservative justices as corporate shills.”

Mutual Pharmaceutical Co., Inc. V. Bartlett—Catch-22 for the Generic Pharmaceutical Agency

By | IP Law Alert | July 10, 2013
Mutual Pharmaceutical Co., Inc. V. Bartlett—Catch-22 for the Generic Pharmaceutical Agency

The generic pharmaceutical industry faced a Catch-22 when a serious adverse reaction arose from use of a generic drug product, and the manufacturer was restrained from unilaterally amending the product label to conform to state requirements, due to the Supreme Court’s decision in PLIVA, Inc. v. Mensing, 131 S.Ct. 2567 (2011).

The Worst Supreme Court Cases of 2013 for Consumers, Employees, and Patients

Back in January 2012, I posted a short item titled, Supreme Court Sets The Tone For 2012 Term: Might Makes Right, in which I recounted how the Supreme Court had begun the 2011-2012 term with two opinions that were great if you own a prison management company or fake credit repair company, but not so great if you were injured by a private prison’s malfeasance or defrauded by a consumer credit company.